{"id":"mebeverine","rwe":[{"pmid":"41529917","year":"2026","title":"Evaluation of safety and efficacy of the combination of mebeverine and sulpiride in treatment of patients with functional gastrointestinal disorders: A prospective cohort.","finding":"","journal":"The Journal of international medical research","studyType":"Clinical Study"},{"pmid":"41486987","year":"2026","title":"Vascular Pharmacology Patent on Mebeverine.","finding":"","journal":"Current cardiology reviews","studyType":"Clinical Study"},{"pmid":"41454995","year":"2025","title":"Development and evaluation of chitosan-xanthan gum-based controlled release nanoparticles of mebeverine hydrochloride for targeted IBS therapy: in silico, in vitro, and in vivo investigations.","finding":"","journal":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","studyType":"Clinical Study"},{"pmid":"41297650","year":"2026","title":"Smart bioconjugated MOFs for targeted drug delivery: Albumin and globulin effects on mebeverine release dynamics.","finding":"","journal":"Nanomedicine : nanotechnology, biology, and medicine","studyType":"Clinical Study"},{"pmid":"41153861","year":"2025","title":"Correction: Milusheva et al. In Silico, In Vitro, and Ex Vivo Biological Activity of Some Novel Mebeverine Precursors. Biomedicines 2023, 11, 605.","finding":"","journal":"Biomedicines","studyType":"Clinical Study"}],"tags":[{"label":"mebeverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AA04","category":"atc"},{"label":"Active","category":"status"},{"label":"Irritable bowel syndrome","category":"indication"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":149.332,"date":"","count":35,"signal":"Catarrh","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=149)"},{"llr":146.347,"date":"","count":36,"signal":"Burns second degree","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=146)"},{"llr":145.719,"date":"","count":36,"signal":"Steroid dependence","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=146)"},{"llr":124.829,"date":"","count":42,"signal":"Gingival pain","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=125)"},{"llr":122.467,"date":"","count":36,"signal":"Hypopnoea","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=122)"},{"llr":119.597,"date":"","count":55,"signal":"Nightmare","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=120)"},{"llr":116.869,"date":"","count":59,"signal":"Accidental overdose","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=117)"},{"llr":106.935,"date":"","count":35,"signal":"Parosmia","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=107)"},{"llr":106.656,"date":"","count":57,"signal":"Swollen tongue","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=107)"},{"llr":84.707,"date":"","count":36,"signal":"Rhinitis","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=85)"},{"llr":84.211,"date":"","count":38,"signal":"Cardiac murmur","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=84)"},{"llr":82.253,"date":"","count":52,"signal":"Tinnitus","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=82)"},{"llr":82.234,"date":"","count":39,"signal":"Bronchiectasis","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=82)"},{"llr":79.578,"date":"","count":35,"signal":"Impaired quality of life","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=80)"},{"llr":69.472,"date":"","count":39,"signal":"Frequent bowel movements","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=69)"}],"commonSideEffects":[{"effect":"Headache","drugRate":"14.8%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":155,"totalAffected":23,"trialsReporting":1},{"effect":"Nausea","drugRate":"7.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":155,"totalAffected":11,"trialsReporting":1},{"effect":"Asthenia","drugRate":"3.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":155,"totalAffected":5,"trialsReporting":1}],"seriousAdverseEvents":[{"event":"Covid-19 Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MEBEVERINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:28:21.792369+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:28:27.705224+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEBEVERINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:28:28.085363+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:56:28.728221+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1446650/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:28:28.793200+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:39:01.977355+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:56:28.728209+00:00"}},"allNames":["mebeverine","mebeverine hydrochloride","CSAG 144","mebeverine HCl"],"offLabel":[],"synonyms":["mebeverine","mebeverine hydrochloride","CSAG 144","mebeverine HCl"],"timeline":[],"approvals":[],"ecosystem":[{"indication":"Irritable bowel syndrome","otherDrugs":[{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"clidinium","slug":"clidinium","company":"Roche"},{"name":"dicycloverine","slug":"dicycloverine","company":"Forest Labs Inc"},{"name":"homatropine","slug":"homatropine","company":""}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"mebeverine","explanation":"","oneSentence":"","technicalDetail":"Mebeverine acts as a spasmolytic agent, specifically targeting the smooth muscle of the gastrointestinal tract to inhibit spasmodic contractions and reduce pain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1642","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MEBEVERINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEBEVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:30:56.966259","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:39:03.520660+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"oxyphencyclimine","drugSlug":"oxyphencyclimine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dicycloverine","drugSlug":"dicycloverine","fdaApproval":"1950-05-11","relationship":"same-class"}],"genericName":"mebeverine","indications":{"approved":[{"name":"Irritable bowel syndrome","source":"DrugCentral","snomedId":10743008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"oxyphencyclimine","brandName":"oxyphencyclimine","genericName":"oxyphencyclimine","approvalYear":"","relationship":"same-class"},{"drugId":"dicycloverine","brandName":"dicycloverine","genericName":"dicycloverine","approvalYear":"1950","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05815602","phase":"PHASE3","title":"Ebastine Versus Mebeverine in IBS Patients","status":"RECRUITING","sponsor":"Guy Boeckxstaens","startDate":"2023-03-30","conditions":["IBS - Irritable Bowel Syndrome","IBS"],"enrollment":200,"completionDate":"2028-01-01"},{"nctId":"NCT05175131","phase":"PHASE3","title":"Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders","status":"COMPLETED","sponsor":"Abbott","startDate":"2020-11-27","conditions":["Functional Bowel Disorder"],"enrollment":465,"completionDate":"2021-05-18"},{"nctId":"NCT06914921","phase":"NA","title":"Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome.","status":"COMPLETED","sponsor":"S.LAB (SOLOWAYS)","startDate":"2024-02-04","conditions":["Irritable Bowel Syndrome (IBS)"],"enrollment":224,"completionDate":"2025-02-01"},{"nctId":"NCT05508633","phase":"PHASE2","title":"The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Changzheng Hospital","startDate":"2022-10-28","conditions":["Portal Hypertension"],"enrollment":20,"completionDate":"2025-12"},{"nctId":"NCT06696248","phase":"PHASE2,PHASE3","title":"Carvedilol and Alverine in Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-11-15","conditions":["Hypertension, Portal"],"enrollment":30,"completionDate":"2025-09-30"},{"nctId":"NCT06473493","phase":"PHASE2,PHASE3","title":"The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06","conditions":["Hypertension, Portal"],"enrollment":30,"completionDate":"2025-03"},{"nctId":"NCT06470386","phase":"PHASE2,PHASE3","title":"The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06","conditions":["Hypertension, Portal"],"enrollment":178,"completionDate":"2025-11"},{"nctId":"NCT05867550","phase":"PHASE4","title":"To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea","status":"COMPLETED","sponsor":"Bahria University","startDate":"2023-01-03","conditions":["Irritable Bowel Syndrome With Diarrhea"],"enrollment":162,"completionDate":"2023-06-10"},{"nctId":"NCT05523427","phase":"NA","title":"Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"University of Mosul","startDate":"2022-07-19","conditions":["Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea"],"enrollment":100,"completionDate":"2023-01-06"},{"nctId":"NCT05100719","phase":"NA","title":"The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)","status":"NOT_YET_RECRUITING","sponsor":"University of Pecs","startDate":"2022-09","conditions":["Irritable Bowel Syndrome","Lactose Intolerance","Lactose Malabsorption"],"enrollment":200,"completionDate":"2026-12"},{"nctId":"NCT00934973","phase":"PHASE4","title":"Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)","status":"COMPLETED","sponsor":"Hazel Everitt","startDate":"2010-04","conditions":["Irritable Bowel Syndrome"],"enrollment":135,"completionDate":"2011-10"},{"nctId":"NCT04635566","phase":"NA","title":"Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2019-03-01","conditions":["Incontinence","Urinary Incontinence","Urinary Bladder Cancer"],"enrollment":120,"completionDate":"2020-03-01"},{"nctId":"NCT03147599","phase":"PHASE4","title":"Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2017-05-15","conditions":["Oncology","Incontinence","Incontinence, Daytime Urinary","Incontinence, Nighttime Urinary","Bladder Cancer","Orthotopic Neobladder"],"enrollment":110,"completionDate":"2019-05-01"},{"nctId":"NCT04145856","phase":"PHASE4","title":"Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico","status":"COMPLETED","sponsor":"Hospital Juarez de Mexico","startDate":"2018-09-03","conditions":["Irritable Bowel Syndrome"],"enrollment":55,"completionDate":"2019-08-27"},{"nctId":"NCT04217733","phase":"PHASE3","title":"Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome","status":"RECRUITING","sponsor":"Tanta University","startDate":"2019-11-01","conditions":["IBS - Irritable Bowel Syndrome"],"enrollment":60,"completionDate":"2030-12-30"},{"nctId":"NCT02260154","phase":"","title":"Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm","status":"COMPLETED","sponsor":"Abbott","startDate":"2015-07","conditions":["Post-cholecystectomy Gastrointestinal Spasms"],"enrollment":220,"completionDate":"2016-10"},{"nctId":"NCT03549143","phase":"","title":"Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation","status":"COMPLETED","sponsor":"Abbott","startDate":"2017-12-25","conditions":["Irritable Bowel Syndrome"],"enrollment":1000,"completionDate":"2019-04-19"},{"nctId":"NCT01404923","phase":"PHASE4","title":"Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Laboratoires Mayoly Spindler","startDate":"2009-12","conditions":["Irritable Bowel Syndrome"],"enrollment":436,"completionDate":"2011-10"},{"nctId":"NCT01678781","phase":"","title":"Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide","status":"COMPLETED","sponsor":"Abbott","startDate":"2012-07","conditions":["Irritable Bowel Syndrome"],"enrollment":607,"completionDate":"2013-08"},{"nctId":"NCT00542295","phase":"PHASE4","title":"Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Laboratoires Mayoly Spindler","startDate":"2007-07","conditions":["Irritable Bowel Syndrome"],"enrollment":400,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003995","UNII":"7F80CC3NNV","CHEBI":"CHEBI:91514","INN_ID":"1191","RXNORM":"235827","UMLSCUI":"C0065832","chemblId":"CHEMBL1446650","ChEMBL_ID":"CHEMBL282121","KEGG_DRUG":"D04868","DRUGBANK_ID":"DB12554","PUBCHEM_CID":"4031","SNOMEDCT_US":"349819003","IUPHAR_LIGAND_ID":"9011","SECONDARY_CAS_RN":"2753-45-9","MESH_SUPPLEMENTAL_RECORD_UI":"C005096"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":206,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AA04","allCodes":["A03AA04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan","pmid":"41529917","title":"Evaluation of safety and efficacy of the combination of mebeverine and sulpiride in treatment of patients with functional gastrointestinal disorders: A prospective cohort.","journal":"The Journal of international medical research"},{"date":"2026 Jan 2","pmid":"41486987","title":"Vascular Pharmacology Patent on Mebeverine.","journal":"Current cardiology reviews"},{"date":"2025 Dec 27","pmid":"41454995","title":"Development and evaluation of chitosan-xanthan gum-based controlled release nanoparticles of mebeverine hydrochloride for targeted IBS therapy: in silico, in vitro, and in vivo investigations.","journal":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences"},{"date":"2026 Jan","pmid":"41297650","title":"Smart bioconjugated MOFs for targeted drug delivery: Albumin and globulin effects on mebeverine release dynamics.","journal":"Nanomedicine : nanotechnology, biology, and medicine"},{"date":"2025 Oct 21","pmid":"41153861","title":"Correction: Milusheva et al. In Silico, In Vitro, and Ex Vivo Biological Activity of Some Novel Mebeverine Precursors. Biomedicines 2023, 11, 605.","journal":"Biomedicines"}],"companionDiagnostics":[],"structuredTrialResults":[{"hr":"1.1","nctId":"NCT05175131","phase":"PHASE3","pValue":"0.0042","ciLower":"0.3","ciUpper":"1.8","endpoint":"Change From Baseline of Sum of NRS-11 Abdominal Pain and Bloating/Flatulence Intensity Scores After 4 Weeks of Treatment.","enrollment":465}],"genericManufacturerList":[],"status":"active","brandName":"MEBEVERINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mebeverine is a small molecule used to treat conditions such as Irritable Bowel Syndrome (IBS) and Portal Hypertension. It has been studied in clinical trials in combination with other interventions, including Ebastine and Peppermint Oil, for the treatment of IBS.","enrichmentLevel":5,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:39:03.520660+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}